Market Overview

Teva Says Omacetaxine Mepesuccinate Shows Activity in CML

Related TEVA
Benzinga's M&A Chatter for Tuesday March 31, 2015
Canaccord Hot And Cold On Deals By Teva Pharmaceutical, ImmunoGen
Dyax Soars As Rare-Disease Drug Wows Wall Street (Investor's Business Daily)

Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.

Posted-In: News FDA


Related Articles (TEVA)

Around the Web, We're Loving...